Advances in genomics of SGLT2 and clinical application of SGLT2 inhibitors
10.12206/j.issn.2097-2024.202302006
- VernacularTitle:钠−葡萄糖协同转运蛋白2的基因组学研究进展及其抑制剂的临床应用
- Author:
Xiaoxia DENG
1
;
Jing TIAN
2
;
Jianfen SU
3
Author Information
1. Department of Pharmacy, The Panyu Central Hospital Affiliated to Guangzhou Medical University, Guangzhou 511400, China.
2. Department of Pharmacy, The First Affiliated Hospital of Naval Medical University, Shanghai 200433, China.
3. Department of Pharmacy, The Panyu Central Hospital Affiliated to Guangzhou Medical University, Guangzhou 511400, China;Department of Pharmacy, The First Affiliated Hospital of Naval Medical University, Shanghai 200433, China.
- Publication Type:Reviews
- Keywords:
pharmacogenomics;
gene polymorphism;
type 2 diabetes mellitus;
SGLT2 inhibitor
- From:
Journal of Pharmaceutical Practice and Service
2026;44(5):228-232
- CountryChina
- Language:Chinese
-
Abstract:
Sodium-glucose cotransporter 2 （SGLT2） is involved in most glucose reabsorption in the kidney. Inhibition of SGLT2 leads to the excretion of glucose through urine and represents an important concept in the treatment of type 2 diabetes. With the development of pharmacogenomics, it was found that SGLT2 gene polymorphism had certain effects on fasting blood glucose, glycosylated hemoglobin and insulin levels, and may affect the risk of type 2 diabetes and response to treatment with SGLT2 inhibitors, which is of great significance in the treatment of T2DM. Domestic and international studies on SGLT2 gene polymorphism were reviewed and effects of SGLT2 inhibitor （SGLT2i） in the treatment of T2DM were discussed in this paper.
